COVID-19 allowed governments to critically examine the biopharma space to increase access to vaccines, but there's still a way to go, according to Monique Mansoura, PhD, MBA, executive director of global health security and biotechnology at the MITRE Corporation, at the International Generic and Biosimilar Medicines Association’s annual meeting.
Monique Mansoura, PhD, MBA, executive director of global health security and biotechnology at the MITRE Corporation, explained the intricacies of how geopolitical issues, like the COVID-19 pandemic and inflation, impact pharmaceuticals and contribute to ongoing drug supply shortages.
The annual meeting of the International Generic and Biosimilar Medicines Association (IGBA) was held in Orlando, Florida, from February 15 to February 16.
How has the COVID-19 pandemic contributed to supply chain issues within the pharmaceutical industry, including biologics and biosimilars?
Mansoura: From my perspective, the most dramatic evidence of this intersection of COVID-19 and supply chains with medical pharmaceuticals, is the recognition of the criticality of these assets for national and economic security.
In large part, it's because of the access to diagnostics, therapeutics, and of course, vaccines that allowed in large part the restoration to some sort of new normal, if you will, of how we go about our daily lives—school, work, play. And it was, again, in large part access.
So, the intersection of national security with the biopharma medical supply ecosystem, industrial-based supply chain has been core to the work we've been doing at MITRE and the work that I've been doing in various capacities over the last 20-plus years.
Beside the COVID-19 pandemic, how have other geopolitical issues factored into drug supply shortages and government entities abilities to address them?
Mansoura: This heightened awareness of how important access to medicines, drugs, and again, what we would call national security assets, COVID-19 vaccines, has really been heightened by not only COVID-19, of course, but I think through the CHIPS [the Creating Helpful Incentives to Produce Semiconductors] and Science Act, the broader discussions that are going on in the US and around the world about access to key technologies, whether it's semiconductors or AI [artificial intelligence] or autonomous vehicles, electric batteries, or Russian oil.
I think an awareness of the resiliency, the surety, and security of access to key assets like that, that really are critical to our national and economic security. I think many of us—as consumers but also as professionals in this space—have responsibilities to ensure sort of the surety and security of access to critical assets. There is clearly a shift in in attention to this through legislation, through policy, through executive orders, and through everyday public discourse. So, clearly heightened sensitivity.
13 Strategies to Avoid the Nocebo Effect During Biosimilar Switching
December 18th 2024A systematic review identified 13 strategies, including patient and provider education, empathetic communication, and shared decision-making, to mitigate the nocebo effect in biosimilar switching, emphasizing the need for a multifaceted approach to improve patient perceptions and therapeutic outcomes.
Biosimilars Policy Roundup for September 2024—Podcast Edition
October 6th 2024On this episode of Not So Different, we discuss the FDA's approval of a new biosimilar for treating retinal conditions, which took place in September 2024 alongside other major industry developments, including ongoing legal disputes and broader trends in market dynamics and regulatory challenges.
Commercial Payer Coverage of Biosimilars: Market Share, Pricing, and Policy Shifts
December 4th 2024Researchers observe significant shifts in payer preferences for originator vs biosimilar products from 2017 to 2022, revealing growing payer interest in multiple product options, alongside the increasing market share of biosimilars, which contributed to notable reductions in both average sales prices and wholesale acquisition costs.
The Rebate War: How Originator Companies Are Fighting Back Against Biosimilars
November 25th 2024Few biologics in the US have multiple biosimilar competitors, but originator biologics respond quickly to competition by increasing rebates and lowering net prices, despite short approval-to-launch timelines for biosimilars.